Rambarack, Naiomi
Fodder, Katherine
Murthy, Megha
Toomey, Christina
de Silva, Rohan
Heutink, Peter
Humphrey, Jack
Raj, Towfique
Lashley, Tammaryn
Bettencourt, Conceição
Funding for this research was provided by:
Alzheimer’s Research UK
Medical Research Council (MR/N013867/1)
Multiple System Atrophy Trust
Reta Lila Weston Trust for Medical Research
CurePSP
EU Joint Programme - Neurodegenerative Disease Research
NOMIS Foundation
National Institute of Neurological Disorders and Stroke (U54NS123743, U54NS123743)
Alzheimer’s Society
Association of Frontotemporal Dementia
Article History
Received: 12 February 2025
Accepted: 23 June 2025
First Online: 5 July 2025
Declarations
:
: The post-mortem tissues used to generate the FTLD1 datasets were obtained from brains donated to the Queen Square Brain Bank, where the tissues are stored under a licence from the Human Tissue authority (No. 12198). The brain donation programme and protocols have been granted ethical approval for donation and research by the NRES Committee London Central. The post-mortem tissues used to generate the FTLD2 datasets were obtained from The Netherlands Brain Bank (NBB), Netherlands Institute for Neuroscience, Amsterdam. All NBB Material has been collected from donors for whom a written informed consent was obtained for a brain donation and the use of the material and clinical information for research purposes. The FTLD3 DNA methylation dataset was accessed through a public repository (GEO accession number GSE75704). As described by Weber et al. [], the use of human brain tissue to generate that dataset had been approved by the ethics committees of the University of Giessen and of the Technical University of Munich. All brain samples were from patients who had given informed consent before death.
: Not applicable.
: The authors declare no competing interests.